[{"data":1,"prerenderedAt":237},["ShallowReactive",2],{"$f1qxopjqy5rsdb":3},{"schema":4,"slug":5,"series":6,"series_slug":7,"name":8,"year":9,"therapeutic_area":10,"generated_at":11,"counts":12,"top_targets":21,"top_modalities":54,"top_diseases":82,"top_companies":113,"key_results":143,"trends":225,"previous_editions":234,"comparison":149,"highlighted_classes":235},1,"eadv-2026","EADV","eadv","EADV Congress 2026",2026,"Dermatology","2026-11-05T22:19:09Z",{"abstracts":13,"drug_linked":14,"companies":15,"by_phase":16},2239,1195,170,{"Phase 1":17,"Phase 1\u002F2":4,"Phase 2":18,"Phase 4":19,"Phase 2\u002F3":4,"Phase 3":20},4,33,7,74,[22,26,30,33,36,40,43,47,49,52],{"name":23,"count":24,"share":25},"JAK1",120,10,{"name":27,"count":28,"share":29},"GR",92,8,{"name":31,"count":32,"share":19},"IL4R",89,{"name":34,"count":35,"share":19},"IL-17A",81,{"name":37,"count":38,"share":39},"IL13RA1",77,6,{"name":41,"count":42,"share":17},"IL23A",50,{"name":44,"count":45,"share":46},"IL-13",41,3,{"name":48,"count":45,"share":46},"JAK2",{"name":50,"count":51,"share":46},"IL23R",38,{"name":53,"count":18,"share":46},"IL17F",[55,59,63,66,69,73,76,79],{"name":56,"count":57,"share":58},"Small molecules",746,62,{"name":60,"count":61,"share":62},"Monoclonal antibodies",376,31,{"name":64,"count":65,"share":39},"Bispecific antibodies",68,{"name":67,"count":68,"share":17},"Non-antibody therapeutic proteins",42,{"name":70,"count":71,"share":72},"Peptides",25,2,{"name":74,"count":75,"share":72},"Natural-product mixtures and botanicals",22,{"name":77,"count":78,"share":72},"Vaccines",21,{"name":80,"count":81,"share":72},"Carbohydrate, lipid and polymer therapeutics",19,[83,87,90,93,97,100,103,106,108,111],{"name":84,"count":85,"share":86},"atopic dermatitis (AD)",193,16,{"name":88,"count":89,"share":29},"psoriasis",100,{"name":91,"count":92,"share":19},"plaque psoriasis",78,{"name":94,"count":95,"share":96},"alopecia areata",57,5,{"name":98,"count":99,"share":96},"hidradenitis suppurativa (HS)",54,{"name":101,"count":102,"share":46},"acne vulgaris",34,{"name":104,"count":105,"share":72},"chronic idiopathic urticaria (CIU)",28,{"name":107,"count":105,"share":72},"Vitiligo",{"name":109,"count":110,"share":72},"psoriatic arthritis (PsA)",27,{"name":112,"count":75,"share":72},"prurigo nodularis (PN)",[114,117,120,123,126,129,132,135,138,141],{"name":115,"count":116,"share":25},"Pfizer",122,{"name":118,"count":119,"share":29},"AbbVie",90,{"name":121,"count":122,"share":19},"Regeneron Pharmaceuticals",82,{"name":124,"count":125,"share":96},"Eli Lilly",58,{"name":127,"count":128,"share":96},"Novartis",56,{"name":130,"count":131,"share":17},"Genentech",46,{"name":133,"count":134,"share":17},"Johnson & Johnson",44,{"name":136,"count":137,"share":46},"Sanofi",37,{"name":139,"count":140,"share":46},"GSK",36,{"name":142,"count":102,"share":46},"Bayer",[144,153,160,167,173,180,187,193,200,206,212,219],{"title":145,"drug":146,"company":149,"phase":150,"disease":84,"finding":151,"url":152},"60-Week Efficacy Maintenance and Relapse Control with MG-K10 in Adults with Moderate-to-Severe Atopic Dermatitis: MG-K10 Phase 3 Long-Term Extension Results",{"name":147,"slug":147,"named_as":148},"comekibart","MG-K10",null,"Phase 3","Regarding efficacy maintenance, among patients in the MG-K10 treatment group who achieved EASI-75 or IGA 0\u002F1 with a ≥2-point reduction from baseline at Week 16, 98.9% maintained EASI-75 response and 92.6% maintained IGA response at Week 52.","https:\u002F\u002Feadvdistribute.m-anage.com\u002Ffrom.storage?image=D1sNQbkNJ-1GueSF7ZEalpen8eXbjGWlcjSSAYZAt8s04cpRGq3XLctd3fpvUm_Z0",{"title":154,"drug":155,"company":157,"phase":150,"disease":91,"finding":158,"url":159},"Efficacy and Safety of Gumokimab, a novel IL-17A mAb, in Patients with Moderate to Severe Plaque Psoriasis: A Randomized, Double-blind, Placebo-controlled, Multicenter Phase III Clinical Study",{"name":156,"slug":156},"gumokimab","Akeso","Same trend also was found in PASI 100 response rates in gumokimab groups with 48.0% (150mg group) and 52.0% (300mg group) at week 12; and 68.9% (150mg group) and 74.8% (300mg group) at week 52.","https:\u002F\u002Feadvdistribute.m-anage.com\u002Ffrom.storage?image=D1sNQbkNJ-1GueSF7ZEalrdUWqgJCtzGZIgCixxaTeobhWQQiht3UfDxhOb8ZHLj0",{"title":161,"drug":162,"company":164,"phase":150,"disease":91,"finding":165,"url":166},"The updated results of the 12-week period of the phase III, randomized, double-blind, placebo-controlled study BCD-085-16\u002FPLANETA-KIDS: Netakimab efficacy and safety in pediatric patients with moderate-to-severe plaque psoriasis",{"name":163,"slug":163},"netakimab","Biocad","Over a 12-week period Netakimab showed a favorable safety profile: 34.9% (29\u002F83) of patients in the Netakimab group reported AEs (vs 40.0% in the Placebo group, and 45.9% - in the Adalimumab group).","https:\u002F\u002Feadvdistribute.m-anage.com\u002Ffrom.storage?image=D1sNQbkNJ-1GueSF7ZEalmEuuvQ2VI0Yhi1c87uXTroEqMPhz4xMzjVmtz5nL6TL0",{"title":168,"drug":169,"company":149,"phase":150,"disease":84,"finding":171,"url":172},"Efficacy and safety of manfidokimab (AK120) in adults with moderate-to-severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial",{"name":170,"slug":170},"manfidokimab","Serious adverse events (SAEs) were reported in 2.5% (manfidokimab) and 2.8% (placebo) of patients, respectively, with the majority considered unrelated to the treatment.","https:\u002F\u002Feadvdistribute.m-anage.com\u002Ffrom.storage?image=D1sNQbkNJ-1GueSF7ZEalgWzeOl1gumT2VAHo1fRhWgChdk3pAWjpO7E84wdl6ru0",{"title":174,"drug":175,"company":149,"phase":150,"disease":84,"finding":178,"url":179},"Efficacy and Safety of SSGJ-611 in Chinese Patients with Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial",{"name":176,"slug":177},"SSGJ-611","ssgj-611","During the 16-week treatment period, treatment-emergent adverse event (TEAE) occurred in 66.1% (228\u002F345) of patients in the SSGJ-611 group and 65.5% (114\u002F174) in the placebo group.","https:\u002F\u002Feadvdistribute.m-anage.com\u002Ffrom.storage?image=D1sNQbkNJ-1GueSF7ZEalmGiOnSvvikQifUkA55PGDhS3R0ydPGiTsnj2T46AYX10",{"title":181,"drug":182,"company":184,"phase":150,"disease":84,"finding":185,"url":186},"Ruxolitinib Cream Use to Delay or Prevent Treatment Escalation in Adults With Moderate Atopic Dermatitis Eligible for Systemic Therapy: Results From the TRuE-AD4 Study",{"name":183,"slug":183},"ruxolitinib","Incyte","Disease control was also evident with the mean reduction in affected BSA from baseline (15.1%) to Week 8 (2.5%) being maintained at Week 24 (2.5%) with as-needed application of ruxolitinib cream.","https:\u002F\u002Feadvdistribute.m-anage.com\u002Ffrom.storage?image=D1sNQbkNJ-1GueSF7ZEalmgGjY6KO9eQSoj8ehD3jPt9kC1rWh37-jfNrT15jakS0",{"title":188,"drug":189,"company":149,"phase":150,"disease":84,"finding":191,"url":192},"Efficacy and safety of Telikibart for moderate to severe atopic dermatitis: a randomized placebo-controlled, phase Ⅲ trial",{"name":190,"slug":190},"telikibart","A higher IGA 0\u002F1 response was also observed in the Telikibart group (33.1% vs. 6.6%; difference, 26.5% [95% CI, 19.86-33.15]; P \u003C0.0001).","https:\u002F\u002Feadvdistribute.m-anage.com\u002Ffrom.storage?image=D1sNQbkNJ-1GueSF7ZEalq4nZKYW8eCwk3vjAwD-pYTG58JzrkkiHbs3y-xN8cS20",{"title":194,"drug":195,"company":149,"phase":150,"disease":84,"finding":198,"url":199},"Efficacy and Safety of Gecacitinib Tablets in Chinese Adults with Moderate‑to‑Severe Atopic Dermatitis: A Multicenter Phase III Trial",{"name":196,"slug":196,"named_as":197},"jaktinib","gecacitinib","During the main study, adverse events (AEs) were reported in 95.2%, 93.2%, and 76.4% of participants in the gecacitinib 75 mg, gecacitinib 100 mg, and placebo groups, respectively.","https:\u002F\u002Feadvdistribute.m-anage.com\u002Ffrom.storage?image=D1sNQbkNJ-1GueSF7ZEalj4maeuB9yM-mDqRa6lahdAvZPhYB13Yyan0gIZJo5iZ0",{"title":201,"drug":202,"company":127,"phase":150,"disease":104,"finding":204,"url":205},"Continued improvement of quality of life with remibrutinib in patients with chronic spontaneous urticaria from the 24 week-long randomized withdrawal period of REMIXED extension study",{"name":203,"slug":203},"remibrutinib","Adverse events reported in 42.5% vs 37.6% of patients on remibrutinib versus those on placebo, however, with longer median exposure to remibrutinib (24.0 weeks) than placebo (15.6 weeks).","https:\u002F\u002Feadvdistribute.m-anage.com\u002Ffrom.storage?image=D1sNQbkNJ-1GueSF7ZEalhtLdntci7tWrI2U4gggOT9rNOojTh8MRIJRtCtdCfnO0",{"title":207,"drug":208,"company":133,"phase":150,"disease":91,"finding":210,"url":211},"VISIBLE: Guselkumab Impact on Psoriatic Arthritis Through Week 100 in Participants With Moderate-to-Severe Psoriasis and Uncontrolled Psoriatic Arthritis Across All Skin Tones",{"name":209,"slug":209},"guselkumab","From baseline to Week 16, the GUS-treated group achieved clinically important improvements in mean PsAID-12 score (least-squares mean change, −4.1 vs 0.2 with placebo; nominal p\u003C0.001) and a mean score (2.9) below the PASS threshold.","https:\u002F\u002Feadvdistribute.m-anage.com\u002Ffrom.storage?image=D1sNQbkNJ-1GueSF7ZEalnapJLG2puHc-_coGtJjLcQR_ChqXsuveyaPaAsqI3gv0",{"title":213,"drug":214,"company":216,"phase":150,"disease":84,"finding":217,"url":218},"Tralokinumab monotherapy rapidly improves sleep, daily functions, and health-related quality of life in patients with atopic dermatitis and moderate-to-severe hand involvement",{"name":215,"slug":215},"tralokinumab","LEO Pharma","Response rates continued to improve with continuous tralokinumab treatment up to Week 32 in the open-label period, with clinically meaningful improvements in DLQI and HEIS observed in 89.6% (n\u002FN: 112\u002F125) and 83.2% (99\u002F119) of patients, respectively.","https:\u002F\u002Feadvdistribute.m-anage.com\u002Ffrom.storage?image=D1sNQbkNJ-1GueSF7ZEalnvrNWSHru_ztirCMQMzL5fvyjlVSCVjNBFp0Fa1gnr70",{"title":220,"drug":221,"company":149,"phase":150,"disease":84,"finding":223,"url":224},"Tapinarof Cream 1% Once Daily in Atopic Dermatitis: Individual Patient EASI Responses from Pooled ADORING 1 and ADORING 2 Phase 3 Clinical Trials",{"name":222,"slug":222},"tapinarof","At Week 8, statistically significantly more tapinarof-treated than vehicle-treated patients achieved a vIGA-ADTM response (45.9% vs 15.9%, P\u003C0.0001), based on MI‑estimand analyses, defined as vIGA-ADTM score of 0 or 1 and ≥2 grade improvement from baseline.","https:\u002F\u002Feadvdistribute.m-anage.com\u002Ffrom.storage?image=D1sNQbkNJ-1GueSF7ZEals3ucQEhLhPkdldzzUsL2ZFN43D-ZI3yGfr5j9ieAqon0",{"summary":226,"bullets":228},[227],"Small molecules were the most frequent modality (62% of drug-linked abstracts). JAK1 was the most frequent target (10%). Atopic dermatitis (AD) was the most frequent disease (16%).",[229,230,231,232,233],"Pfizer had the largest company share (10% of drug-linked abstracts).","Bispecific antibodies accounted for 6% of drug-linked abstracts.","Monoclonal antibodies were the next most frequent modality (31%).","GR was the next most frequent target (8%).","Psoriasis was the next most frequent disease (8%).",[],[236],{"name":64,"count":65,"share":39,"previous_count":149,"previous_share":149,"direction":149},1793970603073]